On March 5, 2018, Boston Scientific Corporation, one of the world’s premier medical devices companies, acquired EMcision Limited, a privately-held, top-tier medical device company based in the UK and operating throughout the US.
The acquisition will significantly expand Boston Scientific’s device portfolio; EMcision devices are sold in 38 countries around the world and used in most of the top US cancer centres.
Osler, Hoskin & Harcourt LLP represented EMcision with a team consisting of Shahir Guindi, Raphaël Amram and and Mark Brender (Tax).